NEUROCRINE BIOSCIENCES INC (NBIX) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — NBIX

Balance Sheet

(in billions USD)

Metric	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	0.27	0.34	0.26	0.19	0.35	0.14	0.40	0.29	0.16	0.10	0.21	0.16	0.27	0.31	0.37	0.35
Accounts Receivable	0.77	0.73	0.60	0.52	0.48	0.47	0.45	0.42	0.39	0.39	0.30	0.28	0.26	0.16	0.16	0.15
Inventory	0.06	0.07	0.06	0.06	0.05	0.04	0.04	0.03	0.03	0.03	0.04	0.03	0.03	0.03	0.03	0.03
Total Current Assets	2.44	2.16	1.75	1.64	1.88	1.67	1.80	1.65	1.50	1.43	1.21	1.02	1.02	1.01	1.11	1.09
Property, Plant & Equipment	0.09	0.10	0.09	0.09	0.08	0.08	0.08	0.07	0.07	0.06	0.06	0.07	0.06	0.05	0.05	0.05
Goodwill	--	--	--	--	0.01	0.01	0.01	0.01	0.01	0.01	--	--	--	--	--	--
Intangible Assets	--	0.04	0.04	0.04	0.03	0.03	0.03	0.03	0.04	0.04	--	--	--	--	--	--
Total Non-current Assets*	2.47	2.11	2.14	2.05	1.66	1.64	1.67	1.20	1.12	0.93	0.94	0.99	1.13	1.01	0.85	0.76
Total Assets	4.91	4.27	3.89	3.69	3.54	3.31	3.47	2.85	2.61	2.36	2.14	2.01	2.14	2.02	1.96	1.85
Accounts Payable	0.77	0.58	0.49	0.48	0.39	0.36	0.42	0.50	0.39	0.36	0.30	0.27	0.24	0.21	0.19	0.17
Total Current Liabilities	0.83	0.64	0.55	0.52	0.43	0.40	0.71	0.69	0.58	0.37	0.49	0.29	0.25	0.23	0.21	0.19
Total Non-current Liabilities*	0.67	0.62	0.65	0.63	0.39	0.40	0.37	0.15	0.18	0.30	0.11	0.30	0.50	0.45	0.46	0.45
Total Liabilities	1.50	1.26	1.20	1.15	0.82	0.80	1.09	0.85	0.76	0.68	0.60	0.58	0.75	0.67	0.68	0.64
Retained Earnings	0.59	0.29	0.08	(0.01)	0.08	(0.05)	(0.11)	(0.30)	(0.39)	(0.48)	(0.50)	(0.56)	(0.55)	(0.63)	(0.65)	(0.69)
Total Stockholder Equity	3.41	3.00	2.69	2.54	2.72	2.51	2.39	2.00	1.85	1.68	1.54	1.42	1.39	1.35	1.28	1.21

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Total Revenue	814.50	805.50	794.90	687.50	572.60	627.70	622.10	590.20	515.30	515.20	498.80	452.70	420.40	412.00	387.90	378.20	310.60	312.00	296.00	288.90
Cost of Revenue*	13.80	17.60	14.00	11.30	9.20	9.30	8.00	9.20	7.50	8.50	11.20	11.50	8.50	7.70	6.10	4.80	4.60	4.10	4.20	3.10
Gross Profit	800.70	787.90	780.90	676.20	563.40	618.40	614.10	581.00	507.80	506.70	487.60	441.20	411.90	404.30	381.80	373.40	306.00	307.90	291.80	285.80
Research & Development	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Selling, General & Admin	318.50	301.80	291.60	286.30	276.50	287.80	234.30	242.00	243.10	218.90	204.20	221.80	242.70	182.90	186.30	182.80	200.70	156.50	154.60	143.20
Total Operating Expenses	607.30	577.00	541.90	530.60	539.80	476.40	430.30	435.60	408.50	356.40	346.40	367.60	526.10	300.90	294.00	318.70	302.90	358.50	247.30	223.00
Operating Income	193.40	210.90	239.00	145.60	23.60	142.00	183.80	145.40	99.30	150.30	141.20	73.60	(114.20)	103.40	87.80	54.70	3.10	(36.30)	44.50	62.80
Interest Expense	--	--	--	--	--	--	--	--	1.10	1.10	1.10	1.30	1.10	1.10	1.20	2.20	2.60	6.60	6.60	6.20
Pretax Income	246.80	239.40	291.80	159.50	14.70	162.60	190.30	98.60	34.50	198.20	115.60	121.60	(103.30)	117.90	97.90	(23.30)	21.40	(13.80)	30.50	57.50
Tax Provision	48.90	85.70	82.30	52.00	6.80	59.50	60.50	33.60	(8.90)	50.50	32.50	26.10	(26.70)	28.90	29.40	(6.40)	7.50	(6.50)	8.00	15.20
Net Income	197.90	153.70	209.50	107.50	7.90	103.10	129.80	65.00	43.40	147.70	83.10	95.50	(76.60)	89.00	68.50	(16.90)	13.90	(7.30)	22.50	42.30
Basic EPS	1.97	1.53	2.11	1.09	0.08	1.05	1.28	0.64	0.43	1.52	0.85	0.98	(0.79)	0.92	0.72	(0.18)	0.15	(0.08)	0.24	0.45
Diluted EPS	1.91	1.49	2.04	1.06	0.08	1.00	1.24	0.63	0.42	1.49	0.82	0.95	(0.79)	0.91	0.69	(0.18)	0.14	(0.07)	0.23	0.43

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021
Operating Cash Flow	145.80	388.40	227.50	102.00	64.80	242.50	158.00	64.60	130.30	123.50	212.00	179.60	(125.20)	143.00	98.80	138.10	(40.50)	4.20	61.80	103.20
Capital Expenditures	9.10	(2.40)	13.20	12.50	10.70	7.30	8.10	11.60	11.20	5.40	7.60	6.80	8.50	1.80	(1.70)	8.80	7.60	8.90	5.70	4.30
Free Cash Flow*	136.70	390.80	214.30	89.50	54.10	235.20	149.90	53.00	119.10	118.10	204.40	172.80	(133.70)	141.20	100.50	129.30	(48.10)	(4.70)	56.10	98.90
Investing Cash Flow	(506.20)	(52.90)	(196.70)	(29.00)	14.20	(68.30)	24.70	(28.20)	(55.00)	(201.80)	(97.30)	(125.90)	(42.10)	(115.60)	(61.30)	31.40	(31.60)	23.70	(126.20)	(90.80)
Financing Cash Flow	(86.10)	37.30	45.60	(3.30)	(117.90)	(290.00)	26.40	(293.00)	69.90	35.40	18.80	2.90	8.20	24.60	11.40	(276.40)	6.10	1.80	7.50	3.00

* Derived from reported values